Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Recruiting
Background: * Endocrine neoplasms (tumors) are among the fastest growing tumors in incidence in the United States. Furthermore, it is often difficult to distinguish between benign or malignant tumors in cancers of the thyroid, parathyroid, adrenal gland, and pancreas. More research is needed to improve detection and treatment options for patients who develop these kinds of cancer. * Researchers are interested in studying the molecular changes that are involved in endocrine cancer development an... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
04/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms, Adrenal Neoplasm, Neuroblastoma
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Recruiting
To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors. Then to explore the antitumor effects of the neratinib and sodium valproate combination in advanced solid tumors with attention to RAS-mutated tumors, EGFR-altered GBM, and ocular melanoma, as part of the phase 2 expansion cohort.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Conditions: Solid Tumor, Adult
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Recruiting
Background: Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers. Researchers want to see if the transplant can treat VEXAS Syndrome. Objective: To see if stem cell transplants can be successfully performed in people with VEXAS and even improve the disease. Eligibility: People ages 18-75 who have VEXAS Syndrome that has caused significant health problems and... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Immunodeficiency, Hematopoietic Stem Cell Transplantation
Walking Exercise Sustainability Through Telehealth for Veterans With Lower-limb Amputation
Recruiting
Despite recent advances in physical rehabilitation, Veterans with lower-limb amputation have poor long-term outcomes, including severely limited functional capacity and high levels of disability. Such poor outcomes are compounded by a lack of exercise participation over time, even with use of lower-limb prostheses. There is a clear need to advance current rehabilitation strategies to better promote sustained exercise following lower-limb amputation. To address this need, the study will determine... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
04/15/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado
Conditions: Lower-Limb Amputation
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Recruiting
The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreatment AAV5 Nabs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Michigan - 84000285, Ann Arbor, Michigan +15 locations
Conditions: Hemophilia B
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2025
Locations: Medvin Clinical Research - Metyas ( Site 0128), Covina, California +118 locations
Conditions: Systemic Lupus Erythematosus
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Recruiting
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/15/2025
Locations: USA Mitchell Cancer Institute, Mobile, Alabama +342 locations
Conditions: Large B-cell Lymphoma
Vancomycin Dose Optimization in Obesity
Recruiting
The goal of this clinical trial is to learn how to optimize vancomycin dosing in obese adults based on weight and kidney function. It will also assess the safety of different vancomycin dosing strategies. The main questions it aims to answer are: Does dosing vancomycin based on kidney function provide better drug exposure than dosing based on weight? What medical or safety issues arise when vancomycin is dosed according to weight versus kidney function? Participants will be randomized into two... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/15/2025
Locations: Michigan Clinical Research Unit, Ann Arbor, Michigan
Conditions: Pharmacokinetics and Pharmacodynamics
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Recruiting
Background: - Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system. Objectives: - To collect and st... Read More
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
04/15/2025
Locations: Children's National Medical Center, Washington, District of Columbia +4 locations
Conditions: Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Recruiting
Background: The drug venetoclax treats chronic lymphocytic leukemia (CLL). Researchers want to find better treatments for CLL. To do that, they need to learn how the drug affects CLL cancer cells and the immune system. Objective: To learn about genetic changes that happen during treatment of CLL with venetoclax. Eligibility: Adults ages 18 and older with relapsed or refractory CLL after at least 1 prior therapy Design: Participants will be screened under a separate protocol. In Phase 1,... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Lymphocytic Leukemia
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Accel Research Sites Network - Birmingham- Site Number : 8400003, Birmingham, Alabama +70 locations
Conditions: Systemic Lupus Erythematosus
Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)
Recruiting
Research Type: Clinical Trial Background: People with sickle cell disease (SCD) have many health challenges. Also, they often have trouble sleeping. Acceptance and commitment therapy (ACT) might help people with SCD to improve their sleep problems. Objective: To see how well ACT works in people with SCD and sleep problems and to find out how they feel about it. Eligibility: People between the ages of 18 and 55 with SCD and trouble sleeping. Design: The study is remote. Participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Sickle Cell Anemia, Insomnia, Sleeplessness, Transient Insomnia, Nonorganic Insomnia, Chronic Insomnia